Programs
Pipeline
Cristal Therapeutics is progressing a robust pipeline of nanoparticle therapeutic candidates which are rationally designed to target specific tissues, cells and intracellular components throughout the body.
The Company’s lead candidate, CPC634, a nanoparticle containing docetaxel, is in a Phase 2 clinical study to determine its therapeutic efficacy in the treatment of patients with ovarian cancer and other solid tumours. A confirmatory trial in metastatic castration-resistant prostate cancer is planned in 2020, aiming for registration via the 505(B)(2) / Hybrid 10(3) routes in the USA and Europe respectively.
CPC634 is available for licensing.
Cristal Therapeutics is screening both marketed products and those in development to identify the active pharmaceutical ingredients (APIs) that can benefit the most from the clinical advantages of our CriPec® technology – increased tumour targeting, improved safety profile, improved PK profile, and increased solubility for injectable products.
Cristal Therapeutics has a number of ongoing partnerships and is actively looking for additional collaborations to combine the partner’s proprietary APIs with our CriPec® platform.
CPC289 is centred on a CriPec®-based nanoparticle that entraps dexamethasone, an approved corticosteroid therapeutic for the treatment of inflammation. In vivo proof-of-concept was achieved in two models of chronic inflammation. This exciting application of the CriPec® technology is available for licensing.